Limit of detection
4 pg/mL
Sample dilution
1/500 (Urine from healthy subjects)
Species reactivity (positive)
None
Target
Human NGAL (Neutrophil Gelatinase-Associated Lipocalin)
Background
NGAL is a new early biomarker for diagnosing acute kidney injury (AKI).Under normal conditions, NGAL levels are low in urine and plasma, but they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.
Regulatory status
RUO - Research Use Only
Patent status
This product is protected by one or more US, European and/or foreign patents.
bioporto公司成立于2001年,是丹麦一家专门生产抗体和基于抗体的各种生物产品的公司,目前公司员工有25人。公司致力于生产、销售高质量产品,并提供各种相关服务。
BioPorto拥有Bioporto Diagnostics和Antibody shop两个品牌,分别侧重于诊断试剂盒和抗体产品。在30多个国家有代理商,产品销售网络遍布全球,99%以上为出口销售。BioPorto Diagnostics旗下产品主要为几种临床快速诊断试剂盒,包括诊断早期急性肾损伤的NGAL ELISA kit,评估原发性免疫缺陷的MBL Oligomer ELISA kit,同时还有相关其他种属的科研用试剂盒和抗原抗体。其最新推出的产品有检测人体血浆中的活性蛋白C-蛋白C抑制物(APC-PCI)复合物的APC-PCI ELISA kit,高纯度人IgE单克隆抗体,以及Glucagon-like peptide-1和Exendin-4相关的单抗。